GENinCode PLC - British Medical Journal publication
GENinCode Plc
("GENinCode" or the "Company")
British Medical Journal publication
Study on Avoiding Late Diagnosis of Ovarian Cancer ("ALDO")
The ALDO project is a partnership between the North Central London Cancer Alliance, and Abcodia Ltd (now owned by GENinCode Plc). The partnership was formed in 2017 as part of an NHS-industry challenge to improve the early diagnosis of cancer. The project set an objective of establishing further clinical evidence for the performance and cost-effectiveness of OC surveillance using the ROCA Test, in women with pathogenic BRCA1/2 variants who had deferred risk-reducing surgery. The proprietary algorithm calculates a woman's individual OC risk based on a number of factors including cumulative CA 125 blood test results, age, menopausal status and the presence of a BRCA1 or BRCA2 gene mutation. The CA 125 blood test is a widely available across global healthcare systems offering the prospect of easy adoption of the algorithm.
875 female BRCA1/2-heterozygotes were recruited through 13 UK NHS genetic centres, or via an online media campaign, with 767 women undergoing at least one four-month surveillance with the ROCA Test. Abnormal ROCA results referred women for repeat ROCA Testing or a Transvaginal Ultrasound Scan (TVUS). Surveillance performance was calculated by assessing the presence of OC confirmed at surgery. In an economic analysis, the incremental cost-effectiveness ratio ("ICER") was also calculated.
During the pilot study, conducted over a 30-month period, eight OC cases were identified. Six cases were detected by the ROCA Test and two cases were detected at the point of self-opted risk reducing surgery. Three of the six (50%) surveillance-detected OC cases were confirmed through surgery at stages where there was no visible disease beyond the pelvis. A complete surgical removal of the tumour was possible in five of six (83%) cases. Modelled sensitivity, specificity, PPV and NPV for OC were 87.5% (95%CI, 47.3-99.7), 99.9% (99.9-100), 75% (34.9-96.8) and 99.9% (99.9-100) respectively. The predicted number of quality-adjusted life-years gained by surveillance was 0.179 with an ICER cost-saving of -
The results showed that OC surveillance for women deferring RRSO in a 'real-world' setting is feasible and demonstrated similar performance to the earlier research trials. Surveillance down-stages OC, which enables a more complete cytoreduction, therefore improving patient outcomes and is cost-saving in the
Click https://www.bmj.com/company/newsroom/ovarian-cancer-surveillance-in-women-with-faulty-brca-genes-results-in-earlier-stage-diagnosis/ to read the press release from the BMJ.
For more information visit www.genincode.com
|
GENinCode Plc |
www.genincode.com or via Walbrook PR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) |
Tel: +44 (0)20 7710 7600 |
|
|
|
|
|
|
|
|
|
|
Cenkos Securities Plc (Joint Broker) |
Tel: +44 (0)20 7397 8900 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or |
|
|
|
||
About GENinCode
GENinCode Plc is a
GENinCode operates business units in the
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
About Ovarian Cancer
Ovarian cancer is disease that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs for reproduction. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. Some mutations (changes) in certain genes e.g. in BRCA1 and BRCA2 can increase your risk of developing ovarian cancer.
When ovarian cancer is found in its early stages, long term survival is improved due to more complete tumour resection and more effective treatment. Ovarian cancer is difficult to diagnose through symptom presentation, as the symptoms are vague and present very often only when the cancer has spread beyond the ovaries.
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The American Cancer Society estimates for ovarian cancer in
· Approximately 19,880 women will receive a new diagnosis of ovarian cancer.
· Approximately 12,810 women will die from ovarian cancer.
A woman's risk of ovarian cancer during her lifetime is about 1 in 78. Her lifetime chance of dying from ovarian cancer is about 1 in 108. Ovarian cancer mainly develops in older women. About half of the women who are diagnosed with ovarian cancer are 63 years or older. It is more common in white women than African American women. The rate at which women are diagnosed with ovarian cancer has been slowly falling over the past 20 years.
The ROCA Test offers surveillance for women with a BRCA1 or BRCA2 mutation who are not ready to undertake risk reducing surgery. To read more about the ROCA Test, click <here: www.therocatest.co.uk>
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.
Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to ensure that those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the
Genetic risk assessment can help early detection and treatment of CVD to help patients live longer, healthier lives. Many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people routinely knowing their 'ABC' (testing and monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE